Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported an open-market sale of 2,000 shares of common stock at $90.00 per share on April 16, 2026. Following this transaction, she directly holds 175,371 shares of Apogee common stock.
According to a footnote, this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 2, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
Apogee Therapeutics Chief Executive Officer Michael Thomas Henderson reported open-market sales of company common stock. On April 8, 2026, he sold 17,800 shares at a weighted average price of $82.48, 2,000 shares at $83.26, and 200 shares at $85.00.
These transactions were executed under a Rule 10b5-1 trading plan adopted on August 13, 2025, indicating they were pre-scheduled. Following these sales, Henderson directly holds 1,132,987 shares of Apogee Therapeutics common stock.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 10,291,220 shares of Apogee Therapeutics Inc. common stock, equal to 16.8% of the class as reported. The filing shows sole voting power over 9,762,311 shares and sole dispositive power over 10,291,220 shares. The T. Rowe Price Capital Appreciation Fund is disclosed with an interest of 5,295,932 shares (9.7%). The filing is signed and dated by an authorized officer.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski exercised stock options and sold shares in a planned transaction. He exercised options covering 4,125 shares of common stock at an exercise price of $22.86 per share and received 4,125 shares.
On the same date, he sold a total of 5,500 common shares in open-market trades at weighted average prices of about $84.31, $85.33, and $85.89, leaving him with 208,398 directly held shares. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025. A related option grant represents the right to purchase 175,345 shares vesting monthly through December 18, 2027, subject to continued service.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported routine open-market stock sales under a pre-arranged Rule 10b5-1 trading plan. On April 1, 2026, she sold 900 shares of common stock at a weighted average price of $84.46 and 1,100 shares at a weighted average price of $85.46, across multiple trades within disclosed price ranges. After these sales, she held 177,371 shares of common stock directly.
Apogee Therapeutics’ Chief Financial Officer Jane Henderson reported an open‑market sale of 2,000 shares of common stock at $85.00 per share. The transaction took place on March 25, 2026. After this sale, she directly holds 179,371 shares of Apogee common stock.
According to a footnote, this transaction was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 2, 2025. Such plans allow insiders to sell shares according to a preset schedule, reducing the role of day‑to‑day discretion in timing.
Apogee Therapeutics’ major shareholder Fairmount Funds and its principals report updated ownership just below 10% of the company. Fairmount and affiliates disclose beneficial ownership of up to 9.84% and 9.99% of Apogee’s common stock through a mix of common and non-voting common shares, plus vested options, all subject to a 9.99% beneficial ownership cap. Fund II also entered a 60-day lock-up, agreeing not to sell Apogee securities without underwriter consent following the company’s March 26, 2026 underwritten public offering, and did not purchase securities in that offering.
Apogee Therapeutics Inc amendment to a Schedule 13G/A reports that The Vanguard Group beneficially owns 0 shares of Common Stock, representing 0% of the class following an internal realignment described under SEC Release No. 34-39538. The filing explains certain Vanguard subsidiaries will report separately after the realignment. The form is signed by Ashley Grim on 03/26/2026.
Apogee Therapeutics, Inc. entered an underwriting agreement to issue and sell 5,000,000 shares of common stock at $70.00 per share. Underwriters were granted a 30-day option to buy up to 750,000 additional shares, which was exercised in full on March 25, 2026.
Net proceeds from the offering, including the exercised option, are expected to be approximately $377.4 million after underwriting discounts, commissions and estimated expenses. The transaction is being conducted under an existing shelf registration statement, with a final prospectus supplement filed on March 25, 2026, and is expected to close on March 26, 2026.
Apogee Therapeutics, Inc. is conducting a registered public offering of 5,000,000 shares of its voting common stock at a public offering price of $70.00 per share. The offering is expected to deliver approximately $329.0 million in proceeds to Apogee, before expenses, and the underwriters have a 30-day option to purchase up to an additional 750,000 shares.
The company estimates pro forma net tangible book value per share of $16.64 after this offering, implying immediate dilution of $53.36 per share to new investors. Apogee intends to use net proceeds to fund preclinical studies, clinical trials, manufacturing, commercial readiness, R&D, capital expenditures, working capital and general corporate purposes, and estimates the combined cash resources will fund operations into the first quarter of 2029 under current plans.